A phone app giving temperature warnings to people with COPD
Tests a phone app with temperature warnings in people with COPD.
Plain-language title generated from the registry record
Registry title: A Personalized Mobile Application Providing Temperature-Related Health Risk Warnings and Protective Recommendations for Patients With Chronic Obstructive Pulmonary Disease
Key facts
- Where
- Beijing, ChinaSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT07656142, who can take part
Where in China
- Beijing Anzhen Hospital, Capital Medical UniversityBeijing, ChinaTaking people
- Beijing Huairou HospitalBeijing, ChinaTaking people
- Civil Aviation General HospitalBeijing, ChinaTaking people
- Emergency General HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tiantian Li
- Trial code
- NCT07656142
- Record updated
- 23 October 2026
- Original description
This study will test whether a personalized mobile application that provides temperature-related health risk warnings and protective recommendations can reduce acute exacerbations in people with chronic obstructive pulmonary disease (COPD). Researchers will compare participants who receive the mobile application in addition to usual care with those who receive usual care alone. The main question is whether the mobile application reduces the number of COPD acute exacerbation events over 12 months. The study will also evaluate secondary outcomes including quality of life, functional capacity, symptoms, psychological status, physiological and biochemical indicators, environmental temperature risk perception, and participants' use of the mobile application.Read full original descriptionShow less
Effectiveness of A Personalized Mobile Application Providing Temperature-Related Health Risk Warnings and Protective Recommendations for Patients With Chronic Obstructive Pulmonary Disease
This study will test whether a personalized mobile application that provides temperature-related health risk warnings and protective recommendations can reduce acute exacerbations in people with chronic obstructive pulmonary disease (COPD). Researchers will compare participants who receive the mobile application in addition to usual care with those who receive usual care alone. The main question is whether the mobile application reduces the number of COPD acute exacerbation events over 12 months. The study will also evaluate secondary outcomes including quality of life, functional capacity, symptoms, psychological status, physiological and biochemical indicators, environmental temperature risk perception, and participants' use of the mobile application.
Hospital inclusion criteria:; Tertiary hospitals; Hospitals with respiratory wards that admit patients with COPD; Hospitals with a well-established electronic health record system and follow-up capability; Hospitals able to assign a study coordinator; Patient inclusion criteria:; Age >=40 years and <=80 years, with no restriction on sex; Patients with stable chronic obstructive pulmonary disease; At least 1 severe acute exacerbation requiring hospitalization, or at least 2 moderate acute exacerbations requiring outpatient or emergency care, within the previous year; Local permanent residents with a duration of residence >=6 months; Patients who voluntarily agree to participate, are expected to have good adherence, are able to sign informed consent; Patients who own a smartphone or other smart device; Hospital exclusion criteria:; Primary hospitals or private hospitals; Hospitals unable to cooperate with the study protocol; Patient exclusion criteria:; Patients with asthma; Women who are known to be pregnant or breastfeeding, or who have a positive pregnancy test before cluster randomization; Patients with other diseases that may affect participation in the trial, such as refractory hypertension or severe aphasia; Patients currently receiving psychiatric or psychological treatment that may contaminate study results; Expected survival time <1 year, such as in those with malignant tumors or severe cardiopulmonary disease; Participation in other interventional clinical studies that may affect outcome assessment; Any other circumstances in which the investigator considers the patient unsuitable for participation in this study or at significant risk, such as cognitive impairment preventing understanding of and/or compliance with study procedures and/or follow-up.